Last reviewed · How we verify
Lipanor (CIPROFIBRATE)
At a glance
| Generic name | CIPROFIBRATE |
|---|---|
| Sponsor | Winthrop Pharmaceuticals UK Limited |
| Drug class | ciprofibrate |
| Target | Peroxisome proliferator-activated receptor alpha |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Hypertriglyceridemia
- Mixed hyperlipidemia
Common side effects
Key clinical trials
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- Ciprofibrate and Pre-diabetes (PHASE3)
- Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia (PHASE4)
- Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipanor CI brief — competitive landscape report
- Lipanor updates RSS · CI watch RSS
- Winthrop Pharmaceuticals UK Limited portfolio CI